MTOR and breast cancer: More recently, Yin et al. found that miR-221 mediated tumour cell proliferation and resistance to adriamycin by inhibiting the expression of PTEN, which upregulated the activation of the Akt/mTOR pathway in a breast cancer cell line [108].